Familiarity and Perceptions of Aducanumab in Caregivers of Hawaii Alzheimer's Disease Patients: Results of a Telephone Survey.

Autor:	Goo C; Brain Research, Innovation & Translation Laboratory, Hawaii Pacific Neuroscience, Honolulu, USA.; Neurology, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, USA., Morden F; Brain Research, Innovation & Translation Laboratory, Hawaii Pacific Neuroscience, Honolulu, USA.; Neurology, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, USA., Wong K; Brain Research, Innovation & Translation Laboratory, Hawaii Pacific Neuroscience, Honolulu, USA.; Neurology, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, USA., Aquino S; Brain Research, Innovation & Translation Laboratory, Hawaii Pacific Neuroscience, Honolulu, USA., Kawamura J; Brain Research, Innovation & Translation Laboratory, Hawaii Pacific Neuroscience, Honolulu, USA., Rubel V; Brain Research, Innovation & Translation Laboratory, Hawaii Pacific Neuroscience, Honolulu, USA., Masca S; Brain Research, Innovation & Translation Laboratory, Hawaii Pacific Neuroscience, Honolulu, USA., Gorenflo R; Brain Research, Innovation & Translation Laboratory, Hawaii Pacific Neuroscience, Honolulu, USA., Carrazana E; Brain Research, Innovation & Translation Laboratory, Hawaii Pacific Neuroscience, Honolulu, USA.; Neurology, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, USA., Liow K; Brain Research, Innovation & Translation Laboratory, Hawaii Pacific Neuroscience, Honolulu, USA.; Neurology, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, USA.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2023 Dec 05; Vol. 15 (12), pp. e50001. Date of Electronic Publication: 2023 Dec 05 (Print Publication: 2023).
DOI:	10.7759/cureus.50001
Abstrakt:	Aim: To identify current perceptions of aducanumab among patients with Alzheimer's disease (AD) and their caregivers. Methods: A total of 352 caregivers of AD patients seen at Hawaii's largest multidisciplinary neuroscience center between January 01, 2019, and June 21, 2021, were surveyed by telephone to understand patient and caregiver knowledge, familiarity, and hesitancy toward aducanumab. Results: Thirty-seven percent of caregivers were familiar with aducanumab. Caregivers who were spouses of their respective patients with AD (p=0.0023) had increased odds of familiarity. Additional predictors of aducanumab familiarity included patients with higher mini-mental state examination scores (p=0.0076) and those who received mental stimulation (p=0.007). Conversely, caregivers who identified as native Hawaiian and other Pacific Islanders (NHPI) (p=0.044) or the patient's child (p=0.010) were predictors of decreased familiarity. Only 33% of caregivers familiar with aducanumab believed it to be safe and 56% reported "side effects" as their top concern. Thirty percent of caregivers were moderately ready or very ready to use aducanumab if given the opportunity. Conclusion:  Most caregivers of Hawaii AD patients were unfamiliar with aducanumab. Furthermore, those familiar were hesitant to trial the medication. Improved education and awareness of AD therapies are important, so families and caregivers of AD patients can make more informed decisions regarding AD treatment. Competing Interests: The authors have declared financial relationships, which are detailed in the next section. (Copyright © 2023, Goo et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu